Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update

Core Insights - Quoin Pharmaceuticals reported significant clinical progress in its ongoing studies for QRX003, particularly for Netherton Syndrome and Peeling Skin Syndrome, with positive data indicating improvements in patient conditions [2][3][5] - The company received important regulatory designations, including Orphan Drug Designation from the European Medicines Agency and Rare Pediatric Disease Designation from the U.S. FDA, which are expected to accelerate the development of QRX003 [6][8] - The NETHERTON NOW campaign has been expanded to raise awareness about Netherton Syndrome, highlighting the urgent need for effective treatments [2][4][9] Clinical Developments - Positive clinical data from the pediatric Netherton Syndrome study showed significant improvements in skin condition and reduced itch after six months of treatment with QRX003, with no adverse events reported [3] - The Peeling Skin Syndrome study also reported positive outcomes after 12 weeks of treatment, with improvements in disease severity and quality of life metrics [5] - A second pivotal study for QRX003 targeting Netherton Syndrome has been cleared by the FDA, with recruitment expected to conclude by the end of Q1 2026 [7] Financial Overview - As of June 30, 2025, Quoin had approximately $7.8 million in cash and cash equivalents, which is projected to support operations into Q1 2026 [10] - The company reported a net loss of approximately $3.7 million for Q2 2025, an increase from a net loss of approximately $2.0 million in Q2 2024, primarily due to increased research and development expenditures [11][17] - Total operating expenses for the six months ended June 30, 2025, were approximately $7.75 million, compared to $4.60 million for the same period in 2024 [17]